Premium
Platelet mass has prognostic value in patients with myelodysplastic syndromes
Author(s) -
Bowles Kristian M.,
Warner Brian A.,
Baglin Trevor P.
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06246.x
Subject(s) - platelet , medicine , myelodysplastic syndromes , mean platelet volume , overall survival , survival analysis , body mass index , survival rate , gastroenterology , surgery , bone marrow
Summary Platelet mass (mean platelet volume × platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group – median survival 5 months and 5‐year survival 0%; intermediate platelet mass group – median survival 30 months and 5‐year survival 34%; high platelet mass group median survival – not reached at 82 months follow‐up with a 5‐year survival of 82%. These data provide a simple rapid prognostic index at the time of diagnosis in MDS.